Press release
Feb 17, 2014

Sosei announces initiation of development of two ophthalmic products

Tokyo, Japan – 17 February 2014: Sosei Group Corporation (TSE Mothers Index: 4565), the biopharmaceutical company, today announced that its wholly-owned Japanese subsidiary, Activus Pharma, (“Activus”) has decided to commence preclinical development of two ophthalmic products, APP13002 and APP13007.

Both products have been developed as liquid suspensions with a novel administration route, based on Activus’ milling technology.

APP13002 is an ophthalmic solution for infectious cornea inflammation, infectious conjunctivitis, etc., while APP13007 is an anti-inflammatory ophthalmic solution that is expected to offer a more potent effect compared to existing drugs.

Apart from the above two products, Activus is also focusing on development of novel posterior eye segment medication, for which it has received a NEDO grant.